Evogene (EVGN) - Total Assets
Based on the latest financial reports, Evogene (EVGN) holds total assets worth ILA26.09 Million ILA (≈ $69.94K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EVGN net assets for net asset value and shareholders' equity analysis.
Evogene - Total Assets Trend (2006–2024)
This chart illustrates how Evogene's total assets have evolved over time, based on quarterly financial data.
Evogene - Asset Composition Analysis
Current Asset Composition (December 2024)
Evogene's total assets of ILA26.09 Million consist of 54.2% current assets and 45.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 38.4% |
| Accounts Receivable | ILA1.49 Million | 3.7% |
| Inventory | ILA1.82 Million | 4.6% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA12.20 Million | 30.6% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2006–2024)
This chart illustrates how Evogene's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Evogene (EVGN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evogene's current assets represent 54.2% of total assets in 2024, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 38.4% of total assets in 2024, down from 47.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 30.6% of total assets.
Evogene Competitors by Total Assets
Key competitors of Evogene based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Evogene - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.92 | 1.09 | 5.36 |
| Quick Ratio | 4.41 | 1.03 | 5.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA15.99 Million | ILA2.07 Million | ILA42.15 Million |
Evogene - Advanced Valuation Insights
This section examines the relationship between Evogene's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.12 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -22.0% |
| Total Assets | ILA39.86 Million |
| Market Capitalization | $5.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Evogene's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Evogene's assets decreased by 22.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Evogene (2006–2024)
The table below shows the annual total assets of Evogene from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA39.86 Million ≈ $106.87K |
-21.99% |
| 2023-12-31 | ILA51.10 Million ≈ $137.00K |
-8.95% |
| 2022-12-31 | ILA56.13 Million ≈ $150.47K |
-26.44% |
| 2021-12-31 | ILA76.30 Million ≈ $204.57K |
+6.10% |
| 2020-12-31 | ILA71.92 Million ≈ $192.80K |
+0.77% |
| 2019-12-31 | ILA71.36 Million ≈ $191.32K |
+21.59% |
| 2018-12-31 | ILA58.69 Million ≈ $157.36K |
-24.37% |
| 2017-12-31 | ILA77.60 Million ≈ $208.05K |
-19.15% |
| 2016-12-31 | ILA95.99 Million ≈ $257.34K |
-14.75% |
| 2015-12-31 | ILA112.59 Million ≈ $301.86K |
-11.75% |
| 2014-12-31 | ILA127.59 Million ≈ $342.05K |
-7.08% |
| 2013-12-31 | ILA137.31 Million ≈ $368.13K |
+111.72% |
| 2012-12-31 | ILA64.86 Million ≈ $173.87K |
-4.47% |
| 2011-12-31 | ILA67.89 Million ≈ $182.01K |
+58.36% |
| 2010-12-31 | ILA42.87 Million ≈ $114.94K |
-0.02% |
| 2009-12-31 | ILA42.88 Million ≈ $114.96K |
+26.31% |
| 2008-12-31 | ILA33.95 Million ≈ $91.01K |
+218.19% |
| 2007-12-31 | ILA10.67 Million ≈ $28.60K |
-45.35% |
| 2006-12-31 | ILA19.52 Million ≈ $52.34K |
-- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more